Tetsuya Yamagata

Company: Modalis Therapeutics

Job title: CSO

Bio:

Dr. Yamagata serves as the Chief Scientific Officer at Modalis Therapeutics, advancing the development of a novel therapeutic platform using epigenetic editing technology since 2016. Under his leadership, Modalis’ lead program has emerged as one of the frontrunners among pipelines in burgeoning peer companies. With over 15 years of experience in biotechnology, Dr. Yamagata possesses specialized expertise in immunology, molecular biology, and genetics. His extensive medical background includes dedicated years treating cancer patients with haematological disorders. Leveraging his profound knowledge of biomedical science, Dr. Yamagata aims to address unmet medical needs through tackling the most promising indications for epigenetic medicine.

Seminars:

Epigenetic Editing with CRISPR-GNDM: MDL-101 is a Novel Muscle-Tropic AAV Vector for the Treatment of LAMA2-CMD 9:00 am

MDL-101 demonstrates promising efficacy in dyW mouse disease model of LAMA2-CMD, with optimal vector biodistribution, robust LAMA1 expression and significant improvement in the disease phenotype MDL-101 demonstrates a range of safety profiles in NHPs, exhibiting strong biodistribution to skeletal muscles, robust expression of GNDM, and therapeutically significant induction of LAMA1 mRNA and protein With the…Read more

day: Conference Day Two